The norm, in detail
Biological medicines: faster approval backed by reference agencies
ANMAT Provision 4351/2026 (Official Gazette, Jul 15, 2026)
in forceNATIONAL
Market deregulation
What changed and who it applies to
What changed
ANMAT approves 4 annexes with procedures for post-registration changes to BIOLOGICAL medicinal specialties (vaccines and biologics): safety/efficacy changes, quality changes (manufacturing, equipment, production sites), labeling information, and marketing-authorization extensions. It introduces an 'optimized reliance-based review procedure': to evaluate those changes, ANMAT can lean on evaluations already carried out by 'Reference Regulatory Authorities' (recognized foreign regulatory agencies), instead of repeating the full technical review from scratch. verif · Jul 15, 2026 ↗
In force
Takes effect 30 business days after its publication in the Official Gazette (07/15/2026). verif · Jul 15, 2026 ↗
Who it affects
Laboratories and marketing-authorization holders of biological medicines and vaccines in the REM (Registry of Medicinal Specialties) that need to process post-registration changes (manufacturing/site changes, safety/efficacy changes, labeling, marketing extensions). The reliance mechanism shortens the process when the change was already evaluated by a reference regulatory agency (e.g., FDA, EMA), instead of requiring a full technical review from scratch in Argentina. verif · Jul 15, 2026 ↗
The norm
ANMAT Disposición 4351/2026 (DI-2026-4351-APN-ANMAT#MS), signed on Jul 14, 2026 and published in the Boletín Oficial on Jul 15, 2026 (notice 344377). verif · Jul 15, 2026 ↗
Our reading
This is the same logic behind other procedural trims by the government, like the faster certification process in aviation (R4 · opening and deregulation): instead of requiring Argentina's regulator to redo an analysis a reference regulator already did, ANMAT leans on that work to resolve faster. It lowers the time (and cost) of keeping an already-approved biological product up to date in reference markets, without touching the required quality/safety/efficacy standard. thesis
Where it lands, province by province
Applies the same nationwide
We looked at this rule from each of the five provinces we track and found no effect that lands differently in any of them: it applies the same across the country.
The other rules on this subject36
The IGJ digitizes companies' financial statementsIGJ General Res. 9/2026 (RESOG-2026-9-APN-IGJ#MJ), Official Gazette Jul 2, 2026in force
Domestic trade: price-control and intervention rules fallRes. 12/2026 SIC (Official Gazette Jun 9, 2026)in force
Ley Hojarasca: cleanup of the legal framework (still in the Senate)Bill CD-1/26 (half-sanction May 20, 2026)pending
Ignacio Aredez· Chief analyst
Credentials and track record →
Weekly newsletter · free
Get on board the takeoff
This week’s updates: reforms, RIGI and verified program data and new provinces as they launch. Free.
no spam
we read every one
Fact sheet built on the published rule, with the gaps declared. Back to the reforms
How to read the seals → verif primary source · prob primary source pending · unconf not sufficiently backed · estim our own calculation · thesis our reading